DK0974580T3 - Omega-Cycloalkylprostaglandin E1 derivativer - Google Patents
Omega-Cycloalkylprostaglandin E1 derivativerInfo
- Publication number
- DK0974580T3 DK0974580T3 DK99305735T DK99305735T DK0974580T3 DK 0974580 T3 DK0974580 T3 DK 0974580T3 DK 99305735 T DK99305735 T DK 99305735T DK 99305735 T DK99305735 T DK 99305735T DK 0974580 T3 DK0974580 T3 DK 0974580T3
- Authority
- DK
- Denmark
- Prior art keywords
- omega
- derivatives
- prostaglandin
- cycloalkyl
- hepatopathy
- Prior art date
Links
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000005107 Premature Birth Diseases 0.000 abstract 1
- 206010036590 Premature baby Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 206010000210 abortion Diseases 0.000 abstract 1
- 231100000176 abortion Toxicity 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000016273 neuron death Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22105498 | 1998-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0974580T3 true DK0974580T3 (da) | 2002-09-30 |
Family
ID=16760781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99305735T DK0974580T3 (da) | 1998-07-21 | 1999-07-20 | Omega-Cycloalkylprostaglandin E1 derivativer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6235780B1 (da) |
| EP (1) | EP0974580B1 (da) |
| KR (1) | KR100349964B1 (da) |
| AT (1) | ATE218544T1 (da) |
| DE (1) | DE69901658T2 (da) |
| DK (1) | DK0974580T3 (da) |
| ES (1) | ES2178352T3 (da) |
| PT (1) | PT974580E (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006021998A (ja) * | 2002-07-18 | 2006-01-26 | Ono Pharmaceut Co Ltd | Ｅｐ２アゴニストを有効成分とする月経困難症治療剤 |
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| JP4662926B2 (ja) * | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
| WO2005012232A2 (en) * | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
| EP1661580B1 (en) | 2003-07-25 | 2014-01-08 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
| WO2006043655A1 (ja) | 2004-10-22 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | 吸入用医薬組成物 |
| AR056968A1 (es) * | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| CN101237885B (zh) | 2005-06-03 | 2011-01-19 | 小野药品工业株式会社 | 神经再生和/或保护剂 |
| WO2007079078A1 (en) | 2005-12-29 | 2007-07-12 | Bayer Schering Pharma Aktiengesellschaft | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| TW200833695A (en) | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
| CA2666143A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| US8183286B2 (en) * | 2006-11-16 | 2012-05-22 | Gemmus Pharma Inc. | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN103664973B (zh) * | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| NZ712378A (en) | 2009-10-14 | 2017-05-26 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| WO2011047173A2 (en) | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| SG183126A1 (en) | 2010-02-26 | 2012-09-27 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| CA2869547A1 (en) | 2012-04-12 | 2013-10-17 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| EP2913047B1 (en) | 2012-10-29 | 2019-05-08 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| JP6449166B2 (ja) | 2013-10-15 | 2019-01-09 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
| RU2019119652A (ru) | 2016-12-09 | 2021-01-11 | Селтакссис, Инк. | Ингибиторы лейкотриен-а4-гидролазы |
| US10385007B2 (en) | 2016-12-09 | 2019-08-20 | Celtaxsys, Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase |
| US10202334B2 (en) | 2016-12-09 | 2019-02-12 | Celtaxsys, Inc. | Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4132738A (en) | 1978-02-23 | 1979-01-02 | Miles Laboratories, Inc. | Preparation of 15-deoxy-16-hydroxyprostaglandins |
| US5204371A (en) | 1979-12-10 | 1993-04-20 | Schering Aktiengesellschaft | Pharmaceutically active 9-chloroprostaglandins |
| DE2950027A1 (de) | 1979-12-10 | 1981-06-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel |
| DE3126924A1 (de) | 1981-07-03 | 1983-01-20 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel |
| JPS5883670A (ja) * | 1981-11-13 | 1983-05-19 | Teijin Ltd | プロスタグランデインｅ↓１類の製造法 |
| KR950703527A (ko) * | 1992-10-20 | 1995-09-20 | 후미에 사토 | 프로스타글란딘 유도체 |
| JP3502952B2 (ja) * | 1992-10-20 | 2004-03-02 | 大正製薬株式会社 | プロスタグランジン誘導体 |
| DE4330177A1 (de) * | 1993-08-31 | 1995-03-02 | Schering Ag | Neue 9-Chlor-prostaglandin-derivate |
| JP3579448B2 (ja) * | 1993-12-29 | 2004-10-20 | 大正製薬株式会社 | プロスタグランジン誘導体、その塩およびその使用 |
| JP3506485B2 (ja) * | 1994-04-19 | 2004-03-15 | 大正製薬株式会社 | プロスタグランジン誘導体 |
| JP3162668B2 (ja) * | 1997-02-04 | 2001-05-08 | 小野薬品工業株式会社 | ω−シクロアルキル−プロスタグランジンＥ２誘導体 |
| NO317155B1 (no) * | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| US6262293B1 (en) * | 1997-12-25 | 2001-07-17 | Ono Pharmaceutical Co., Ltd. | ω-Cycloalkly-prostaglandin e2 derivatives |
-
1999
- 1999-07-19 US US09/356,674 patent/US6235780B1/en not_active Expired - Fee Related
- 1999-07-20 ES ES99305735T patent/ES2178352T3/es not_active Expired - Lifetime
- 1999-07-20 DE DE69901658T patent/DE69901658T2/de not_active Expired - Fee Related
- 1999-07-20 AT AT99305735T patent/ATE218544T1/de not_active IP Right Cessation
- 1999-07-20 EP EP99305735A patent/EP0974580B1/en not_active Expired - Lifetime
- 1999-07-20 PT PT99305735T patent/PT974580E/pt unknown
- 1999-07-20 DK DK99305735T patent/DK0974580T3/da active
- 1999-07-21 KR KR1019990029480A patent/KR100349964B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100349964B1 (ko) | 2002-08-22 |
| DE69901658T2 (de) | 2002-11-21 |
| PT974580E (pt) | 2002-10-31 |
| KR20000011866A (ko) | 2000-02-25 |
| EP0974580A1 (en) | 2000-01-26 |
| ES2178352T3 (es) | 2002-12-16 |
| ATE218544T1 (de) | 2002-06-15 |
| EP0974580B1 (en) | 2002-06-05 |
| US6235780B1 (en) | 2001-05-22 |
| DE69901658D1 (de) | 2002-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0974580T3 (da) | Omega-Cycloalkylprostaglandin E1 derivativer | |
| HU9800208D0 (en) | Omega-cycloalkyl-prostaglandin e2-derivatives | |
| ATE260254T1 (de) | Omega-cycloalkyl-prostaglandin e2 derivate | |
| PT1213296E (pt) | Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao | |
| ATE225770T1 (de) | Difluoroprostaglandin-derivate und ihre anwendung | |
| GR3032629T3 (en) | Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation | |
| EP0580268A3 (da) | ||
| NZ506497A (en) | Indole derivatives, pharmaceuticals thereof and their use in lowering intraocular pressure or for the treatment or prevention of glaucoma or ocular hypertension | |
| ATE223411T1 (de) | 1-methylcarbapenem-derivate | |
| GB2115815B (en) | Benzothiazoline compounds | |
| TR200002808T2 (tr) | İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri | |
| AU6291494A (en) | Benzothiazole compound, process for producing the same, and use thereof | |
| KR950008446A (ko) | 시클로헥산 유도체 | |
| NO974745L (no) | 1-£<omega>-(3,4-dihydro-2-naftalenyl)alkyl| cyklisk-amin-derivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder samme | |
| TW208000B (da) | ||
| DE69806640T2 (de) | 17beta-aryl(arylmethyl)oxy(thio)alkyl-androstanderivative | |
| DK1137660T3 (da) | 22S-hydroxycholesta-8,14-dienderivater med meioseregulerende aktivitet | |
| TH59045B (th) | อนุพันธ์อินโดลและสารผสมทางเภสัชกรรมที่ประกอบด้วยสารดังกล่าว |